Afficher la notice abrégée

Metastatic Ewing sarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study

dc.rights.licenseopenen_US
dc.contributor.authorDUCROT, C.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDINART, Derek
dc.contributor.authorBONNEAU, M.
dc.contributor.authorMIGNOT-POSSON, J.
dc.contributor.authorTHIS, M. S. M.
dc.contributor.authorGRINDA, T.
dc.contributor.authorCHAIX, J.
dc.contributor.authorWINTER, S.
dc.contributor.authorGERARD, P.
dc.contributor.authorDUONG, R.
dc.contributor.authorNARCISO, B.
dc.contributor.authorENTZ-WERLE, N.
dc.contributor.authorLAURENCE, V.
dc.contributor.authorLE CESNE, A.
dc.contributor.authorROUQUETTE, P. B.
dc.contributor.authorBOMPAS, E.
dc.contributor.authorVALENTIN, T.
dc.contributor.authorBRAHMI, M.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBELLERA, Carine
dc.contributor.authorTOULMONDE, M.
dc.date.accessioned2024-01-22T08:53:34Z
dc.date.available2024-01-22T08:53:34Z
dc.date.issued2023-10
dc.date.conference2023-10-20
dc.identifier.issn0923-7534en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/187359
dc.description.abstractEnBackground Metastatic Ewing Sarcoma (MES) has a poor prognosis, and therapeutic options are scarce in this rare disease. Large observational studies are needed to improve patients (pts) care and help designing future clinical trials. Methods Treatment characteristics, outcomes, and prognostic factors of pts > 12 year-old treated for a MES in 10 French national reference network centers from 2008 to 2018 and included in the prospective database of the French Sarcoma Group were analyzed. The primary objective was to describe treatment modalities of pts with MES in a real-life setting, including systemic treatment (ST) regimen, access to clinical trials (CT) and loco-regional (LR) procedures. Secondary objectives were to assess pts outcome in terms of time to next treatment (TNT), progression free survival (PFS) and overall survival (OS) for each line of ST, as well as the impact of CT access and LR procedures on TNT, PFS and OS in the metastatic setting. Results 156 pts with MES were included, 80 pts were metastatic from diagnosis, 76 pts had a metastatic relapse. Median follow-up was 76.8 months [66.7; 88.5]. Median age was 21 years (12-86), 44 (28.2%) pts were < 18 year old at metastasis diagnosis. Main primary location was pelvic (34.6%). 147 (94%) pts received ST in the metastatic setting, with a median of 3 lines (IQR 2-5). 102 (65.4%) pts received more than 2 lines. 95 (60.9%) of pts underwent LR procedure for metastasis, including radiation therapy (84.2%), radiological procedures (12.6%) or surgery (8.4%). 30 (31.6%) pts had multiple procedures. Median OS from metastasis diagnosis was 26.6 months [95%CI 21.0; 32.2]. Median TNT was 5.3 months [95%CI 4.9; 5.6] for 1rst line, 5.5 months [95%CI 3.8; 6.8] for 2nd line and 5.5 months [95%CI 3.7; 7.7] and 3.6 months [95%CI 2.5; 4.4] for 3rd and 4rth lines. 66 (44.9%) pts were included in a CT at least once in the metastatic setting, 35 in 1rst line, 28 in 2nd line and 15 and 22 in 3rd and 4rth lines. Conclusions This large multicentric observational study details real-world data on patterns of treatments for pts with MES in France. Detailed ST regimens used, median TNT, PFS and OS according to line and ST regimen as well as factors associated with TNT, PFS and OS will be presented at the meeting.
dc.language.isoENen_US
dc.title.enMetastatic Ewing sarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
dc.typeCommunication dans un congrèsen_US
dc.identifier.doi10.1016/j.annonc.2023.09.1197en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
bordeaux.pageS1051-S1052en_US
bordeaux.volume34en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issuesupplement 2en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.conference.titleESMO Congress 2023en_US
bordeaux.countryesen_US
bordeaux.title.proceedingAbstract Book of the ESMO Congress 2023, 20 - 24 October 2023en_US
bordeaux.teamEPICENE_BPHen_US
bordeaux.conference.cityMadriden_US
bordeaux.identifier.funderIDBayer Corporationen_US
bordeaux.identifier.funderIDInstitut National Du Canceren_US
hal.identifierhal-04408827
hal.version1
hal.date.transferred2024-01-22T08:53:37Z
hal.invitedouien_US
hal.proceedingsouien_US
hal.conference.end2023-10-24
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.date=2023-10&amp;rft.volume=34&amp;rft.issue=supplement%202&amp;rft.spage=S1051-S1052&amp;rft.epage=S1051-S1052&amp;rft.eissn=0923-7534&amp;rft.issn=0923-7534&amp;rft.au=DUCROT,%20C.&amp;DINART,%20Derek&amp;BONNEAU,%20M.&amp;MIGNOT-POSSON,%20J.&amp;THIS,%20M.%20S.%20M.&amp;rft.genre=unknown


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée